β-分泌酶抑制剂研究进展  

Research advances in design and development of β-secretase inhibitors

作　　者：梁爽 李筱筱[1] 华芮萱 戴雪伶[1] LIANG Shuang;LI Xiao-Xiao;HUA Rui-Xuan;DAI Xue-Ling(Beijing Key Laboratory of Bioactive Substances and Functional Food, Beijing Union University, Beijing 100191, China)

机构地区：[1]北京联合大学生物活性物质与功能食品北京市重点实验室,北京100191

出　　处：《生命科学》2018年第5期593-601,共9页Chinese Bulletin of Life Sciences

基　　金：北京市自然科学基金项目(6164030);北京市优秀人才资助项目(2015000020124G049);北京市教委科技计划面上项目(SQKM201511417013);北京联合大学"启明星"大学生科技创新项目(201711417008)

摘　　要：阿尔兹海默病(Alzheimer's disease,AD)是一种退行性的神经性疾病,其主要病理特征为β-淀粉样蛋白(β-amyloid protein,Aβ)的异常聚集及tau蛋白的过度磷酸化。研究发现,β-分泌酶上调在Aβ沉积发生发展过程中具有重要作用。抑制β-分泌酶活性有可能减少淀粉样病变,从而延缓AD病理发生。现结合AD的发病机制对β-分泌酶的特点及β-分泌酶抑制剂的研究进展进行综述。Alzheimer＇s disease（AD） is a neurodegenerative disease characterized by abnormal aggregation of β-amyloid（Aβ） and hyperphosphorylation of tau protein. It has been found that the up-regulation of β-secretase plays an important role in the development of Aβ deposition. Inhibition of β-secretase activity may reduce amyloidosis, thus delaying the occurrence of AD pathology. This paper reviewed the characters of β-secretase and research advances of β-secretase inhibitors combined with the pathogenesis of AD.

关 键 词：阿尔兹海默病 Β-分泌酶 Β-分泌酶抑制剂 

分 类 号：Q51[生物学—生物化学] R749.16[医药卫生—神经病学与精神病学]